Biomea Fusion Stock Drops After Hours Following Phase 1 Weight-Loss Trial Results
Shares of Biomea Fusion, Inc. (BMEA) dropped 28.58% to $0.90 in after-hours trading after closing down 7.35% at $1.26 during regular hours. The slide followed the announcement of initial Phase 1 clinical trial results for BMF-650, an experimental oral drug being developed to treat obesity and weight management.
In the early-stage trial involving 40 participants across five dose groups, BMF-650 showed average weight loss ranging from 1.5% to 3.2% after 29 days in the first four groups, compared to 0.1% for placebo. A higher-dose group achieved a 6.1% average weight drop, though eating habits during study confinement may have influenced those findings. All reported side effects were mild or moderate, with no severe adverse events or treatment stops.
Looking ahead, Biomea Fusion plans to perform additional data analysis and present full study findings at a future medical conference. The company noted that advancing the drug will require longer-term toxicology testing, and it intends to seek a strategic partner to help develop the treatment.
Key points
- Biomea Fusion, Inc. (BMEA) shares sank 28.58% in after-hours trading to $0.90 following a 7.35% decline during regular market hours.
- Phase 1 study data for oral weight-loss candidate BMF-650 showed average weight reductions of 1.5% to 6.1% at Day 29 across dose groups.
- Higher-dose trial participants lost an average of 6.1% of body weight, though participant confinement may have influenced eating habits.
- Safety outcomes were favorable across 40 participants, with no severe adverse events or treatment-related dropouts reported.
- Advancement of BMF-650 will require longer toxicology studies as Biomea Fusion positions the program for potential strategic partnerships.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Why did Biomea Fusion stock fall after hours?
Biomea Fusion stock fell 28.58% in after-hours trading following the release of Phase 1 clinical trial results for its experimental oral obesity drug, BMF-650.
What were the Phase 1 trial results for BMF-650?
Participants in lower-dose cohorts achieved average weight loss of 1.5% to 3.2% at Day 29, while a higher-dose cohort reached 6.1% weight loss. All reported side effects were mild to moderate, with no severe adverse events.
What are Biomea Fusion's next steps for BMF-650?
Biomea Fusion plans to present additional data at a future medical meeting, conduct longer-term toxicology studies, and seek a potential strategic partner for further clinical development.